[{"NetIncomeLoss_1_Q3_USD":-165339.0,"AssetsCurrent_0_Q3_USD":1265144.0,"StockIssuedDuringPeriodValueNewIssues_1_Q3_USD":4714000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q3_USD":-135700000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_1_Q3_USD":0.0,"AccruedLiabilitiesCurrent_0_Q3_USD":46548.0,"CommitmentsAndContingencies_0_Q3_USD":null,"StockholdersEquityNoteStockSplitConversionRatio1_2_Q3_pure":1.0,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"ProceedsFromRelatedPartyDebt_2_Q3_USD":277687.0,"Liabilities_0_Q3_USD":4801234.0,"Cash_0_Q3_USD":1141327.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":0.0,"PaymentsOfStockIssuanceCosts_1_Q3_USD":8100000.0,"FairValueAssetsLevel2ToLevel1TransfersAmount_0_Q3_USD":0.0,"NetCashProvidedByUsedInFinancingActivities_2_Q3_USD":137101092.0,"ProceedsFromIssuanceOfPrivatePlacement_2_Q3_USD":4714000.0,"AssetsHeldInTrustNoncurrent_0_Q3_USD":135702974.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q3_USD":51734.0,"PaymentOfFinancingAndStockIssuanceCosts_2_Q3_USD":3337908.0,"UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_0_Q3_USD":0.0,"IncomeTaxExpenseBenefit_2_Q3_USD":0.0,"TemporaryEquitySharesOutstanding_0_Q3_shares":12716688.0,"TemporaryEquityCarryingAmountAttributableToParent_0_Q3_USD":127166880.0,"RepaymentsOfRelatedPartyDebt_2_Q3_USD":277687.0,"UnrecognizedTaxBenefits_0_Q3_USD":0.0,"NetIncomeLoss_2_Q3_USD":-184708.0,"AdditionalPaidInCapital_0_Q3_USD":5184241.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q3_USD":1141327.0,"EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_2_Q3_pure":0.0,"AccountsPayableCurrent_0_Q3_USD":5186.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_Q3_USD":1141327.0,"LiabilitiesCurrent_0_Q3_USD":51734.0,"NetCashProvidedByUsedInOperatingActivities_2_Q3_USD":-259765.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-184708.0,"TemporaryEquityRedemptionPricePerShare_0_Q3_USD":10.0,"PrepaidExpenseCurrent_0_Q3_USD":123817.0,"StockholdersEquity_0_Q3_USD":5000004.0,"SharePrice_0_Q3_USD":10.0,"PreferredStockSharesAuthorized_0_Q3_shares":1000000.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":136968118.0,"InvestmentIncomeInterest_1_Q3_USD":2974.0,"InvestmentIncomeInterest_2_Q3_USD":2974.0,"OperatingIncomeLoss_1_Q3_USD":-168313.0,"OperatingIncomeLoss_2_Q3_USD":-187682.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_Q3_USD":0.0,"ProceedsFromIssuanceOfCommonStock_2_Q3_USD":135700000.0,"Assets_0_Q3_USD":136968118.0,"ProfitLoss_2_Q3_USD":-184708.0,"IncreaseDecreaseInPrepaidExpense_2_Q3_USD":123817.0,"Ticker":"PNT","CIK":"1811764","name":"THERAPEUTICS ACQUISITION CORP.","OfficialName":"POINT Biopharma Global Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"812904697.0","Country":"United States","Sector":"Consumer Durables","Industry":"Specialty Chemicals","Market":"NASDAQ","SP500":"nan","filed":"20201102"}]